< Back to latest news & events

HGF Presents

Patenting Polymorphs at the EPO

September 2025

Video overview:

Novelty and Inventive Step

  • Prior art must necessarily lead to the claimed polymorph to be novelty destroying
  • Watch out for inherent disclosures in prior art—methods may implicitly produce polymorphs even if structural data isn’t provided.
  • Provide experimental evidence if needed to show prior art does not produce the claimed polymorph.
  • Emphasize any advantages or unexpected properties of the polymorph, ideally supported by data, to support an inventive step, in the application.
  • Highlight advantages of the polymorph versus other forms.

Clarity

  • Provide a clear, precise definition of the polymorph.
  • Clearly define the crystalline form using appropriate physicochemical parameters and measurement conditions.

Sufficiency

  • Clearly describe how to prepare the polymorph. If preparation requires seeding crystals, disclose how to prepare the seed in the application.

Latest updates

The FoodTech Series #1 | Medicament, functional food, nutritive product in the same claim 1: when your own examples no longer support the “improvement”

            The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they ruled on an opposition …

Read article

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article